Radial Optic Neurotomy (RON) — Cost, Top Hospitals & Success Rates | MyMedicPlus

<p><strong>Radial Optic Neurotomy (RON)</strong> is a vitreoretinal surgical procedure designed to treat <strong>central retinal vein occlusion (CRVO)</strong> — one of the most common retinal vascular disorders, second only to diabetic retinopathy. In CRVO, the central retinal vein, which drains all venous blood from the retina, becomes obstructed, typically at the level of the optic nerve head, where it passes through the tight confines of the lamina cribrosa — a sieve-like structure of connective tissue through which the optic nerve fibres and central retinal vessels traverse. This obstruction causes elevated intravascular pressure throughout the venous drainage network, leading to retinal haemorrhages, retinal oedema, dilated and tortuous veins, and vision loss. The most visually significant consequence is <strong>macular oedema</strong> — fluid accumulation in the central retina — which is responsible for the typically profound reduction in central visual acuity.</p><p>The rationale underlying RON is mechanical: the procedure involves performing a pars plana vitrectomy (removal of the vitreous gel) to gain access to the optic nerve head, followed by making one to three small, radial incisions in the nasal aspect of the optic nerve head using a microvitreoretinal (MVR) blade. The hypothesis is that this creates a controlled relaxing incision through the ring-like tissue of the scleral canal surrounding the optic nerve — the <strong>annular ligament</strong> — thereby decompressing the central retinal vein within the optic canal, releasing the obstruction, and allowing venous outflow to improve. Improved venous drainage would be expected to reduce retinal haemorrhages and macular oedema, ultimately improving visual acuity.</p><p>RON was first described by Opremcak and colleagues in 2001 and generated significant enthusiasm in the early 2000s, with multiple case series reporting substantial visual acuity gains. However, controlled studies have been more equivocal, and the subsequent development of highly effective intravitreal pharmacological agents (anti-VEGF injections and corticosteroid implants) has largely displaced RON in routine clinical practice. It is now considered a <strong>selectively used or investigational procedure</strong> rather than a standard-of-care treatment, reserved for cases with specific characteristics or when pharmacological treatment has failed.</p><p>Understanding both the historical context and the current evidence base is essential for patients and clinicians evaluating whether RON remains an appropriate option in any individual clinical scenario.</p>

<p>RON is specifically designed for <strong>central retinal vein occlusion (CRVO)</strong> — a distinct entity from branch retinal vein occlusion (BRVO), which involves a smaller tributary vein and is managed differently. Understanding CRVO is essential to understanding the rationale and expected outcomes of RON.</p><h3>Pathophysiology of CRVO</h3><p>The central retinal vein and central retinal artery share a common adventitial sheath as they pass through the optic nerve within the lamina cribrosa. CRVO is thought to result from: (1) <strong>thrombosis</strong> at the arteriovenous crossing within the optic nerve, where the artery compresses the vein within their shared connective tissue sheath; (2) <strong>haemodynamic factors</strong> including slow venous flow (from hyperviscosity, hypercoagulability, or low ocular perfusion pressure); or (3) <strong>inflammatory or compressive factors</strong> within the optic canal. Risk factors for CRVO include hypertension (present in 70% of cases), diabetes mellitus, glaucoma (elevated intraocular pressure mechanically compresses the vein), hyperlipidaemia, thrombophilia (especially Factor V Leiden, protein C/S deficiency, antiphospholipid antibody syndrome), hyperhomocysteinaemia, and oral contraceptive use in younger women.</p><h3>Classification of CRVO</h3><p><strong>Non-ischaemic CRVO (perfused CRVO):</strong> The more common form (approximately 75% of cases). Retinal capillary perfusion is preserved on fluorescein angiography. Prognosis for visual recovery is better, with up to 50% of patients recovering acuity spontaneously to 20/40 or better. Risk of neovascular complications (new blood vessel growth causing secondary glaucoma) is low (<5%).</p><p><strong>Ischaemic CRVO (non-perfused CRVO):</strong> Approximately 25% of cases. Extensive retinal capillary non-perfusion (>10 disc areas on fluorescein angiography) is present. Prognosis is very poor — most patients retain vision of 20/200 or worse, and the risk of developing neovascular glaucoma (rubeosis iridis with secondary angle closure) is 60% at 4 months if untreated with anti-VEGF or panretinal laser photocoagulation.</p><h3>Macular Oedema in CRVO</h3><p>Macular oedema is the principal cause of vision loss in CRVO. It arises from: breakdown of the blood-retinal barrier due to elevated venous pressure; ischaemia-driven upregulation of vascular endothelial growth factor (VEGF), which directly increases vascular permeability; and inflammatory cytokines released by ischaemic retinal tissue. Chronic macular oedema leads to photoreceptor damage and, if untreated over months, may result in permanent visual loss even after the underlying oedema resolves.</p><h3>What RON Aims to Address</h3><p>RON addresses the mechanical component of CRVO — the compressive obstruction at the lamina cribrosa. By decompressing the vein through incisions at the optic nerve head, the procedure aims to restore venous outflow, reduce venous hypertension, and secondarily allow macular oedema to resolve. This mechanism targets the root cause of CRVO rather than downstream effects (as anti-VEGF therapy does), which is the theoretical appeal of RON.</p>

<p>Given that RON is no longer first-line treatment for CRVO, careful patient selection is crucial. The procedure is most appropriate in specific clinical scenarios where pharmacological management has been inadequate.</p><h3>Historical Inclusion Criteria (From Early RON Series)</h3><p>The early case series of RON by Opremcak et al. (2001) included patients with: CRVO of less than 3 months' duration; best-corrected visual acuity (BCVA) of 20/200 or worse; significant macular oedema on clinical examination and fluorescein angiography; and evidence of both perfused and non-perfused CRVO variants. Some series favoured non-ischaemic CRVO with intact visual potential, while others included ischaemic CRVO without restriction.</p><h3>Contemporary Candidacy Considerations</h3><p>In the current era, RON may be considered in patients with CRVO who meet the following criteria: (1) <strong>Persistent macular oedema despite adequate pharmacological treatment:</strong> Patients who have received multiple intravitreal anti-VEGF injections (at least 3–6 monthly doses) or intravitreal dexamethasone implant with insufficient macular oedema resolution may be candidates for surgical evaluation. (2) <strong>Reasonably preserved visual potential:</strong> Patients with non-ischaemic CRVO or early ischaemic CRVO with some residual foveal function (relative preservation of outer retinal layers on OCT) are more likely to benefit. (3) <strong>Absence of significant fibrovascular proliferation:</strong> Advanced neovascularisation of the disc or iris makes vitreoretinal surgery more complex and alters the risk-benefit ratio.</p><h3>Pre-Operative Investigations</h3><p>Before any consideration of RON, a comprehensive retinal evaluation is mandatory, including: <strong>best-corrected visual acuity (BCVA)</strong> at baseline; <strong>optical coherence tomography (OCT)</strong> of the macula (to quantify central retinal thickness, assess outer retinal layer integrity as a marker of visual potential, and evaluate the vitreoretinal interface); <strong>fluorescein angiography (FA)</strong> to classify CRVO as ischaemic or non-ischaemic based on capillary non-perfusion area; <strong>intraocular pressure (IOP) measurement</strong> to detect concurrent glaucoma; and <strong>systemic workup</strong> to identify and treat underlying risk factors (hypertension, diabetes, hypercoagulable states). The systemic workup should precede and proceed in parallel with ocular treatment.</p><h3>Who Is Not Suitable</h3><p>RON is contraindicated in patients with: extensive ischaemic CRVO with no residual visual potential (chronic outer retinal loss on OCT, BCVA worse than hand motion for more than 12 months); active ocular infection; severe systemic comorbidities precluding surgery; prior vitrectomy making surgical anatomy unfavourable; or neovascular glaucoma requiring immediate different intervention.</p>

<p>RON is performed as a component of pars plana vitrectomy (PPV). The following describes the standard procedure and its variations:</p><h3>Standard RON Technique (Pars Plana Vitrectomy + RON)</h3><p><strong>Step 1 — Pars Plana Vitrectomy (PPV):</strong> Three sclerotomies (small incisions in the sclera, 3.5–4 mm behind the limbus) are created for the light pipe, infusion cannula, and vitreous cutter. Modern 23- or 25-gauge (micro-incision) vitrectomy systems are used to minimise incision size and improve healing. The core vitreous is removed, followed by careful dissection of the posterior hyaloid face from the retinal surface if vitreous-macular traction is present.</p><p><strong>Step 2 — Radial Incisions at the Optic Nerve Head:</strong> Using a microvitreoretinal (MVR) blade or sharp vitreoretinal pick, one to three radial incisions approximately 1–2 mm in length are made on the nasal aspect of the optic nerve head, penetrating the full thickness of the nerve fibre layer into the pre-laminar optic nerve tissue. The depth and exact position of the incisions require precise anatomical knowledge and careful technique to avoid damaging the central retinal artery, which runs adjacent to the vein. Intraoperative haemorrhage from the nerve head is common and expected; fluid-air exchange helps manage this.</p><p><strong>Step 3 — Fluid-Air Exchange and Closure:</strong> The vitreous cavity is filled with balanced saline solution or silicone oil depending on the clinical situation. Sclerotomies are typically suture-closed (standard gauge) or self-sealing (micro-incision systems).</p><h3>RON Combined With Intravitreal Anti-VEGF Injection</h3><p>Some surgeons administer an intravitreal anti-VEGF injection (bevacizumab or ranibizumab) at the time of vitrectomy+RON or in the early post-operative period to address the VEGF-mediated component of macular oedema while the mechanical decompression takes effect. This combined approach has been reported in small case series with encouraging outcomes, though randomised data are lacking.</p><h3>Cannulation of the Central Retinal Vein (Chorioretinal Venous Anastomosis — Alternative Surgical Approach)</h3><p>As an alternative to RON, some surgeons attempt <strong>chorioretinal venous anastomosis</strong> — using a laser or a mechanical needle to create a fistula between the retinal vein and the choroidal circulation, bypassing the obstructed segment. This approach remains experimental and technically demanding, with significant risks of haemorrhage and epiretinal membrane formation. It is not standard practice.</p><h3>Intraoperative Monitoring</h3><p>Most surgeons use intraoperative fundus monitoring systems (wide-angle viewing systems such as BIOM or RESIGHT) to maintain a clear, magnified view of the optic nerve head during the neurotomy incisions. Intraoperative optical coherence tomography (iOCT) is used in some advanced centres to guide precise blade placement and confirm adequate incision depth.</p>

<p>The clinical evidence base for RON is largely derived from non-randomised case series and retrospective studies. The following summarises the reported benefits and their limitations:</p><h3>Visual Acuity Improvement</h3><p>The landmark 2001 Opremcak paper reported a mean gain of approximately 3 lines of Snellen visual acuity in 11 of 11 patients following RON. Subsequent series reported similarly encouraging results, with visual gains of 2–5 lines in 50–75% of patients. A meta-analysis by Weizer et al. (2003) noted a mean improvement from 20/385 pre-operatively to 20/130 post-operatively across published series — a substantial gain, though still in the low vision range for many patients.</p><h3>Macular Oedema Reduction</h3><p>OCT-measured central retinal thickness typically decreases substantially following RON in responders, consistent with improved venous drainage reducing hydrostatic pressure and fluid accumulation at the macula. Central retinal thickness reductions of 100–300 microns have been reported in case series, corroborating the mechanistic hypothesis.</p><h3>Possible Prevention of Neovascular Complications</h3><p>Some reports suggest that resolution of venous hypertension following RON may reduce the stimulus for VEGF production and thereby lower the risk of retinal and iris neovascularisation — the most feared complication of ischaemic CRVO. However, this benefit has not been conclusively proven in controlled studies, and intravitreal anti-VEGF therapy is the established evidence-based approach for preventing neovascular CRVO complications.</p><h3>Caveats and Limitations of the Evidence</h3><p>Multiple limitations must be acknowledged: (1) All published RON series lack randomised control groups; improvement observed may partly reflect the natural history of CRVO, in which spontaneous resolution of macular oedema occurs in 30–50% of non-ischaemic cases. (2) No large-scale randomised controlled trial has compared RON against sham surgery or intravitreal therapy. (3) The procedure has been largely abandoned in many centres, making contemporary comparative data scarce. (4) Complication rates in the non-randomised series are likely underreported. For these reasons, the CRVO guideline of the American Academy of Ophthalmology and the Royal College of Ophthalmologists do not list RON as a standard treatment.</p>

<p>RON carries the risks of any vitreoretinal surgical procedure, plus additional risks specific to the nerve head incisions. The complication profile is a key reason why RON has been largely replaced by pharmacological approaches in routine practice.</p><h3>Vitreous Haemorrhage</h3><p>Intraoperative haemorrhage at the optic nerve head, arising from the incised tissue or pre-existing engorged retinal veins, is the most common intraoperative complication. Post-operative vitreous haemorrhage occurs in 10–30% of reported cases and may require fluid-air exchange or blood settlement time before vision improves. Most haemorrhages clear spontaneously within weeks; dense or non-clearing haemorrhages may require re-vitrectomy.</p><h3>Retinal Detachment</h3><p>Pars plana vitrectomy carries an inherent risk of iatrogenic retinal breaks and rhegmatogenous retinal detachment, estimated at 1–5% in large vitrectomy series. In the context of RON, the risk may be at the higher end given the complexity of the procedure and the pre-existing retinal pathology.</p><h3>Choroidal Neovascular Membrane (CNV)</h3><p>The incisions made at the optic nerve head can inadvertently penetrate into the subretinal space or Bruch's membrane, stimulating the growth of abnormal choroidal new vessels (subretinal neovascularisation). This complication has been reported in 3–10% of RON cases in some series and can cause additional vision loss, compounding the damage from the original CRVO.</p><h3>Worsening Vision</h3><p>Not all patients improve after RON. Vision can remain unchanged or deteriorate due to surgical complications, progression of retinal ischaemia, or epiretinal membrane formation — a fibrocellular membrane that can form on the retinal surface following vitrectomy and cause macular distortion. Epiretinal membrane formation rates of 10–20% have been reported following RON.</p><h3>Optic Nerve Damage</h3><p>Imprecise blade placement can damage optic nerve fibres directly, compounding visual field loss. The central retinal artery runs immediately adjacent to the vein in the optic canal; inadvertent arterial injury would cause catastrophic vision loss from central retinal artery occlusion. This risk underscores the requirement for high surgical expertise.</p><h3>Standard Surgical Risks</h3><p>General risks include: infection (endophthalmitis — rare but potentially devastating, approximately 0.05% per procedure); cataract development or progression (vitrectomy accelerates posterior subcapsular cataract in phakic patients); elevated intraocular pressure post-operatively; and anaesthesia-related risks.</p>

<p>Post-operative management following RON requires close monitoring both for surgical healing and for assessment of retinal and macular response to the procedure.</p><h3>Immediate Post-Operative Period (Days 1–14)</h3><p>Post-operative medications include topical antibiotic drops (e.g., moxifloxacin or tobramycin), topical corticosteroid drops (e.g., prednisolone 1% or dexamethasone), and cycloplegic drops if ciliary spasm is present. Intraocular pressure is measured at day 1 and week 1 to detect post-operative IOP spikes, which are treated with topical or systemic anti-glaucoma medications. The patient should be instructed to report any sudden decrease in vision, increasing pain, increased redness, or onset of floaters immediately, as these may indicate haemorrhage, retinal detachment, or endophthalmitis.</p><h3>Monitoring Schedule</h3><p>Typical follow-up visits are scheduled at: Day 1 (IOP, wound check, anterior chamber assessment); Week 1 (clinical examination, IOP, fundoscopy); Month 1 (OCT of macula — assess central retinal thickness response; BCVA); Month 3 (OCT, BCVA, fluorescein angiography to assess perfusion status); Month 6 and Month 12 (long-term retinal and macular assessment, check for late complications including epiretinal membrane and choroidal neovascularisation).</p><h3>Adjuvant Intravitreal Therapy</h3><p>If macular oedema persists or recurs following RON, intravitreal anti-VEGF injections (bevacizumab, ranibizumab, or aflibercept) or an intravitreal dexamethasone implant (Ozurdex) can be administered in the post-operative period. The vitreous has been removed (vitrectomised eye), which may alter the pharmacokinetics of intravitreal drugs — shorter half-life has been reported for some agents in vitrectomised eyes, potentially requiring higher frequency dosing.</p><h3>Management of Systemic Risk Factors</h3><p>Medical optimisation of systemic risk factors is an essential and often overlooked component of CRVO management. Patients with hypertension, diabetes, or hyperlipidaemia must work with their general practitioner or internist to optimise systemic control. Patients under 50 with CRVO should undergo a haematological workup for thrombophilia (including Factor V Leiden, prothrombin mutation, protein C/S, antithrombin III, and antiphospholipid antibodies). Low-dose aspirin may be recommended based on the underlying cause.</p>

<p>RON, as a vitreoretinal surgical procedure, is considerably more expensive than intravitreal injection therapy per episode, though it may be competitive if the intent is to achieve a durable result with fewer interventions. Cost data are limited given the procedure's decreased utilisation.</p><h3>Estimated Costs by Region</h3><p><strong>United States:</strong> Pars plana vitrectomy + RON in a hospital ambulatory surgery setting typically costs USD $8,000–$20,000 including surgeon fee, facility fee, and anaesthesia. Where covered by Medicare or private insurance for CRVO, patient out-of-pocket costs may be substantially lower (standard deductibles and copays apply).</p><p><strong>United Kingdom:</strong> As RON is not a standard NHS procedure for CRVO (intravitreal ranibizumab/aflibercept are NICE-approved), this would typically be available only privately. Private vitreoretinal surgery in the UK ranges from GBP £3,000–£7,000.</p><p><strong>India:</strong> Vitreoretinal surgery at top-tier eye hospitals (LV Prasad, Sankara Nethralaya, Aravind, Narayana Nethralaya) costs approximately INR 50,000–1,50,000 (USD $600–$1,800), representing excellent value for medical tourism patients.</p><p><strong>Thailand / Singapore:</strong> USD $3,000–$8,000 at accredited international hospitals with experienced vitreoretinal departments.</p><h3>Comparison with Intravitreal Therapy Costs</h3><p>The cost comparison with intravitreal anti-VEGF therapy requires a long-term perspective. A single bevacizumab (Avastin, off-label) injection costs approximately USD $50–$200 in the USA; ranibizumab (Lucentis) USD $1,800–$2,000 per injection; and aflibercept (Eylea) USD $1,800 per injection. CRVO patients on anti-VEGF therapy typically receive monthly injections for 6–12 months, then PRN — cumulative costs can reach USD $15,000–$30,000 over the first year with branded agents. From a cost-effectiveness perspective, a single surgical intervention that provides durable resolution would be cost-effective if complications are avoided; the challenge is that durable resolution is not reliably achieved.</p><h3>Factors Influencing RON Procedure Cost</h3><ul><li>Gauge of vitrectomy system (25-gauge micro-incision may have higher disposable costs)</li><li>Whether combined with anti-VEGF injection</li><li>Type of anaesthesia (general vs. local retrobulbar)</li><li>Surgeon expertise and centre volume</li><li>Post-operative monitoring requirements</li></ul>

<p>Current evidence-based treatment guidelines for CRVO with macular oedema prioritise pharmacological intravitreal therapies over surgery as first-line management. RON and surgical alternatives represent secondary or investigational options.</p><h3>Intravitreal Anti-VEGF Therapy (First-Line Standard of Care)</h3><p>The landmark CRUISE trial (ranibizumab) and subsequent COPERNICUS and GALILEO trials (aflibercept) established intravitreal anti-VEGF therapy as the evidence-based standard of care for CRVO-associated macular oedema. Monthly ranibizumab injections improved BCVA by a mean of 14–15 ETDRS letters (approximately 3 lines) at 6 months, with 46–48% of patients gaining 15 or more letters — substantially outperforming sham injection controls. Bevacizumab (off-label) is widely used in resource-limited settings at far lower cost. Aflibercept, with its dual VEGF-A and PlGF inhibition, is similarly effective. Monthly injections for the first 3–6 months, followed by a treat-and-extend or PRN protocol, represent best practice. The main limitation is the need for repeated injections over a prolonged period.</p><h3>Intravitreal Dexamethasone Implant (Ozurdex)</h3><p>The GENEVA trial established the intravitreal dexamethasone implant (0.7 mg, Ozurdex, Allergan/AbbVie) as effective for CRVO macular oedema — achieving significant visual acuity gains and central retinal thickness reduction at 2 months post-injection. The implant gradually biodegrades over 6 months. It is particularly valuable in patients who are poor candidates for frequent anti-VEGF injections, those with inflammatory CRVO, and in pseudophakic or aphakic patients (to avoid steroid-induced cataract). Risks include steroid-induced IOP elevation and cataract progression.</p><h3>Intravitreal Triamcinolone Acetonide (IVTA)</h3><p>Before anti-VEGF therapy became available, IVTA was widely used for CRVO macular oedema. While modestly effective, it is now largely superseded by anti-VEGF agents and the dexamethasone implant in most settings. It remains available in resource-limited environments.</p><h3>Laser Photocoagulation</h3><p>Panretinal photocoagulation (PRP) does not treat macular oedema in CRVO but is the standard prophylactic treatment for ischaemic CRVO to prevent neovascular complications (neovascular glaucoma, vitreous haemorrhage). Grid laser photocoagulation of the macular area was shown to be ineffective for CRVO macular oedema in the CVOS study and is not recommended for this indication. Laser remains relevant in the CRVO management pathway for specific neovascular complications.</p><h3>Observation</h3><p>For non-ischaemic CRVO with mild macular oedema and good initial visual acuity (20/40 or better), a period of observation (1–3 months) may be appropriate, as spontaneous resolution occurs in a proportion of patients. Anti-VEGF or steroid therapy is initiated if oedema persists or worsens, or if visual acuity declines.</p>